EUVIMEDEUVIMED entdecken
Open Access

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters

Michihito Sasaki iD, Koshiro Tabata, Mai Kishimoto iD, Yukari Itakura iD, Hiroko Kobayashi iD, Takuma Ariizumi iD, Kentaro Uemura iD, Shinsuke Toba, Shinji Kusakabe, Yuki Maruyama iD, Shun Iida iD, Noriko Nakajima und 10 weitere

Science Translational Medicine · 18.01.2023 · 15 (679)

DOI: 10.1126/scitranslmed.abq4064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 18.01.2023. Verfasst von Michihito Sasaki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In parallel with vaccination, oral antiviral agents are highly anticipated to act as countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oral antiviral medication demands not only high antiviral activity but also target specificity, favorable oral bioavailability, and high metabolic stability. Although a large number of compounds have been identified as potential inhibitors of SARS-CoV-2 infection in vitro, few have proven to be effective in vivo. Here, we show that oral administration of S-217622 (ensitrelvir), an inhibitor of SARS-CoV-2 main protease (M pro ; also known as 3C-like protease), decreases viral load and ameliorates disease severity in SARS-CoV-2–infected hamsters. S-217622 inhibited viral proliferation at low nanomolar to submicromolar concentrations in cells. Oral administration of S-217622 demonstrated favorable pharmacokinetic properties and accelerated recovery from acute SARS-CoV-2 infection in hamster recipients. Moreover, S-217622 exerted antiviral activity against SARS-CoV-2 variants of concern, including the highly pathogenic Delta variant and the recently emerged Omicron BA.5 and BA.2.75 variants. Overall, our study provides evidence that S-217622, an antiviral agent that is under evaluation in a phase 3 clinical trial (clinical trial registration no. jRCT2031210350), has remarkable antiviral potency and efficacy against SARS-CoV-2 and is a prospective oral therapeutic option for COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansCricetinaeSARS-CoV-2Viral LoadProspective StudiesProtease InhibitorsViral Nonstructural ProteinsAntiviral AgentsCoronavirus 3C ProteasesIndazolesTriazinesTriazoles

Substanzen

Protease InhibitorsViral Nonstructural ProteinsAntiviral Agents3C-like proteinase, SARS-CoV-2Coronavirus 3C ProteasesensitrelvirIndazolesTriazinesTriazoles

Autor:innen und Institutionen

  • Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
  • Shionogi & Co. Ltd., Osaka 561-0825, Japan.
  • Laboratory of Biomolecular Science, Faculty of Pharmaceutical Science, Hokkaido University, Sapporo 060-0812, Japan.
  • Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Sapporo 001-0020, Japan.
  • National Virus Reference Laboratory, School of Medicine, University College of Dublin, Dublin 4, Ireland.

ORCID-Profile: Michihito Sasaki, Mai Kishimoto, Yukari Itakura, Hiroko Kobayashi, Takuma Ariizumi, Kentaro Uemura, Yuki Maruyama, Shun Iida, Tadaki Suzuki, Shinpei Yoshida, Haruaki Nobori, Takao Sanaki, Teruhisa Kato, Takao Shishido, William W Hall, Yasuko Orba, Hirofumi Sawa

Zitieren

APA

Sasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., Maruyama, Y., Iida, S., Nakajima, N., Suzuki, T., Yoshida, S., Nobori, H., Sanaki, T., Kato, T., Shishido, T., Hall, W. W., …, & Sawa, H. (2023). S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Science Translational Medicine, 15(679). https://doi.org/10.1126/scitranslmed.abq4064

Vancouver

Sasaki M, Tabata K, Kishimoto M, Itakura Y, Kobayashi H, Ariizumi T, et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Science Translational Medicine. 2023;15(679). doi:10.1126/scitranslmed.abq4064

BibTeX
@article{Sasaki2023,
  author = {Sasaki, Michihito and Tabata, Koshiro and Kishimoto, Mai and Itakura, Yukari and Kobayashi, Hiroko and Ariizumi, Takuma and Uemura, Kentaro and Toba, Shinsuke and Kusakabe, Shinji and Maruyama, Yuki and Iida, Shun and Nakajima, Noriko and Suzuki, Tadaki and Yoshida, Shinpei and Nobori, Haruaki and Sanaki, Takao and Kato, Teruhisa and Shishido, Takao and Hall, William W and Orba, Yasuko and Sato, Akihiko and Sawa, Hirofumi},
  title = {S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {679},
  doi = {10.1126/scitranslmed.abq4064}
}
Kostenlos starten →